{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:10Z","timestamp":1792787830714,"version":"4.5.0"},"reference-count":47,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"crossref","award":["Doctoral Research Scholarship [275179]"],"award-info":[{"award-number":["Doctoral Research Scholarship [275179]"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GSK Canada Ltd."}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,2,24]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Clinically important deterioration (CID), a composite of exacerbation, declines in lung function and health status has been studied as an indicator of disease worsening in moderate\u2013severe COPD clinical populations. We assessed whether CID is predictive of worsening over 18\u2005months in a population-based mild\u2013moderate COPD cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Canadian Cohort Obstructive Lung disease (CanCOLD) participants with COPD were assessed over 18\u2005months for CID, and over the next 18\u2005months for outcomes. Their association was then examined: 1) defined into threshold-based binary variables, the declines in forced expiratory volume in 1\u2005s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ), health status and dyspnoea, using logistic regression models; 2) time to moderate\/severe exacerbation and rates of moderate\/severe exacerbations using Cox proportional hazards and Poisson regression, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 420 participants, 252 (60%) demonstrated CID (definition 1, St George's Respiratory Questionnaire (SGRQ)). Presence of CID at 18\u2005months showed association with future moderate\/severe exacerbation (not statistically significant), worsening health status (COPD Assessment Test (CAT) score), and dyspnoea. As a component, FEV\n                      <jats:sub>1<\/jats:sub>\n                      was found to be less informative, compared with exacerbation for health status outcome (OR 4.31, 95% CI 1.29\u201314.41 for \u22658-unit increase in SGRQ) alongside future exacerbation, and SGRQ health status component, for future health status decline (OR 0.33, 95% CI 0.17\u20130.66 for \u22654-unit increase in SGRQ and OR 0.53, 95% CI 0.30\u20130.94 for \u22652-unit increase CAT score).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our finding of informative CID components seems to support recommendations of emphasis on exacerbation history and health status, over severity of airway obstruction in clinical assessments to predict outcomes. Suitable adaptations of the current CID definition may be needed for mild\u2013moderate COPD populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01172-2024","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T10:58:04Z","timestamp":1742900284000},"page":"01172-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinically important deterioration in a mild\u2013moderate COPD population"],"prefix":"10.1183","volume":"11","author":[{"given":"Sharmistha","family":"Biswas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Doiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn D.","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2498-9859","authenticated-orcid":false,"given":"Kenneth R.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-4651","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Maltais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy D.","family":"Marciniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7593-2433","authenticated-orcid":false,"given":"Denis","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don D.","family":"Sin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandie","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Nadeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Compton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7649-038X","authenticated-orcid":false,"given":"Jean","family":"Bourbeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"2025110310350864000_11.5.01172-2024.1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-11-122"},{"key":"2025110310350864000_11.5.01172-2024.2","doi-asserted-by":"publisher","DOI":"10.1177\/0022034511421200"},{"key":"2025110310350864000_11.5.01172-2024.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00838-2020"},{"key":"2025110310350864000_11.5.01172-2024.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202106-1439OC"},{"key":"2025110310350864000_11.5.01172-2024.5","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-017-0597-7"},{"key":"2025110310350864000_11.5.01172-2024.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0321-7"},{"key":"2025110310350864000_11.5.01172-2024.7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1513\/pats.200701-013FM","article-title":"Assessment tools for chronic obstructive pulmonary disease: do newer metrics allow for disease modification?","volume":"4","author":"Mahler","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"2025110310350864000_11.5.01172-2024.8","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . Global strategy for prevention, diagnosis, and management of chronic obstructive pulmonary disease 2023 report. Date last accessed: 24 February 2023. https:\/\/goldcopd.org\/wp-content\/uploads\/2023\/03\/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf"},{"key":"2025110310350864000_11.5.01172-2024.9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2147\/COPD.S101612","article-title":"Prevention of clinically important deteriorations in COPD with umeclidinium\/vilanterol","volume":"11","author":"Singh","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025110310350864000_11.5.01172-2024.10","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200053377"},{"key":"2025110310350864000_11.5.01172-2024.11","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050513"},{"key":"2025110310350864000_11.5.01172-2024.12","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.10.847"},{"key":"2025110310350864000_11.5.01172-2024.13","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.6.1321"},{"key":"2025110310350864000_11.5.01172-2024.14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00102509"},{"key":"2025110310350864000_11.5.01172-2024.15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S2213-2600(14)70001-3","article-title":"Minimum clinically important difference for the COPD assessment test: a prospective analysis","volume":"2","author":"Kon","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2025110310350864000_11.5.01172-2024.16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12931-020-1280-y","article-title":"Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis","volume":"21","author":"Bafadhel","year":"2020","journal-title":"Respir Res"},{"key":"2025110310350864000_11.5.01172-2024.17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12931-018-0928-3","article-title":"Long-term outcomes following first short-term clinically important deterioration in COPD","volume":"19","author":"Naya","year":"2018","journal-title":"Respir Res"},{"key":"2025110310350864000_11.5.01172-2024.18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12931-017-0583-0","article-title":"Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium\/formoterol","volume":"18","author":"Singh","year":"2017","journal-title":"Respir Res"},{"key":"2025110310350864000_11.5.01172-2024.19","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S133307"},{"key":"2025110310350864000_11.5.01172-2024.20","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.2147\/COPD.S267249","article-title":"Clinically important deterioration among patients with chronic obstructive pulmonary disease (COPD) treated with nebulized glycopyrrolate: a post hoc analysis of pooled data from two randomized, double-blind, placebo-controlled studies","volume":"15","author":"Kerwin","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025110310350864000_11.5.01172-2024.21","doi-asserted-by":"crossref","first-page":"00663","DOI":"10.1183\/23120541.00663-2020","article-title":"Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis","volume":"7","author":"Han","year":"2021","journal-title":"ERJ Open Res"},{"key":"2025110310350864000_11.5.01172-2024.22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","article-title":"Efficacy of umeclidinium\/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial","volume":"20","author":"Maltais","year":"2019","journal-title":"Respir Res"},{"key":"2025110310350864000_11.5.01172-2024.23","doi-asserted-by":"crossref","first-page":"00047","DOI":"10.1183\/23120541.00047-2018","article-title":"Preventing clinically important deterioration with single-inhaler triple therapy in COPD","volume":"4","author":"Naya","year":"2018","journal-title":"ERJ Open Res"},{"key":"2025110310350864000_11.5.01172-2024.24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12890-021-01510-w","article-title":"One-year clinically important deterioration and long-term clinical course in Japanese patients with COPD: a multicenter observational cohort study","volume":"21","author":"Abe","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2025110310350864000_11.5.01172-2024.25","doi-asserted-by":"crossref","first-page":"1753466620977376","DOI":"10.1177\/1753466620977376","article-title":"Modified and simplified clinically important deterioration: multidimensional indices of short-term disease trajectory to predict future exacerbations in patients with chronic obstructive pulmonary disease","volume":"14","author":"Zhao","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"2025110310350864000_11.5.01172-2024.26","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2012.665520"},{"key":"2025110310350864000_11.5.01172-2024.27","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00243-2018"},{"key":"2025110310350864000_11.5.01172-2024.28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/15412550902918402","article-title":"Defining disease modification in chronic obstructive pulmonary disease","volume":"6","author":"Halpin","year":"2009","journal-title":"COPD"},{"key":"2025110310350864000_11.5.01172-2024.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201612-2531OC"},{"key":"2025110310350864000_11.5.01172-2024.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-021-00236-w"},{"key":"2025110310350864000_11.5.01172-2024.31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3904\/kjim.2019.314","article-title":"Cut-off value of FEV1\/FEV6 to determine airflow limitation using handheld spirometry in subjects with risk of chronic obstructive pulmonary disease","volume":"36","author":"Hwang","year":"2021","journal-title":"Korean J Intern Med"},{"key":"2025110310350864000_11.5.01172-2024.32","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00208613"},{"key":"2025110310350864000_11.5.01172-2024.33","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1014OC"},{"key":"2025110310350864000_11.5.01172-2024.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105482"},{"key":"2025110310350864000_11.5.01172-2024.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-699X.2010.00198.x"},{"key":"2025110310350864000_11.5.01172-2024.36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12931-020-01387-z","article-title":"Measuring disease activity in COPD: is clinically important deterioration the answer?","volume":"21","author":"Singh","year":"2020","journal-title":"Respir Res"},{"key":"2025110310350864000_11.5.01172-2024.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411532"},{"key":"2025110310350864000_11.5.01172-2024.38","first-page":"339","article-title":"Dysanapsis in normal lungs assessed by the relationship between maximal flow, static recoil, and vital capacity","volume":"121","author":"Mead","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"2025110310350864000_11.5.01172-2024.39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6918"},{"key":"2025110310350864000_11.5.01172-2024.40","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2147\/COPD.S111724","article-title":"Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease","volume":"11","author":"Camiciottoli","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025110310350864000_11.5.01172-2024.41","first-page":"277","article-title":"New developments in the assessment of COPD: early diagnosis is key","volume":"9","author":"Csikesz","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025110310350864000_11.5.01172-2024.42","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201204-0596PP"},{"key":"2025110310350864000_11.5.01172-2024.43","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S87766"},{"key":"2025110310350864000_11.5.01172-2024.44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1471-2466-14-163","article-title":"Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial","volume":"14","author":"Goossens","year":"2014","journal-title":"BMC Pulm Med"},{"key":"2025110310350864000_11.5.01172-2024.45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S2213-2600(15)00157-5","article-title":"Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data","volume":"3","author":"Soriano","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2025110310350864000_11.5.01172-2024.46","unstructured":"Pahal P , Hashmi MF , Sharma S . Chronic Obstructive Pulmonary Disease Compensatory Measures. 2023 Jun 26. In: StatPearls. Treasure Island, FL, StatPearls Publishing; 2024."},{"key":"2025110310350864000_11.5.01172-2024.47","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1164\/rccm.200811-1757ST","article-title":"An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease","volume":"182","author":"Eisner","year":"2011","journal-title":"Am J Respir Crit Care Med"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01172-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:35:18Z","timestamp":1762194918000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01172-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1183\/23120541.01172-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01172-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]}}}